Globavir seeks approval to develop new Ebola drug
The company, which has the worldwide exclusive license to develop and market GBV006, is seeking approval for the use of the product, a combination of Food and Drug
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted